相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma
Jason Westin et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Challenges and Opportunities in the Management of Diffuse Large B Cell Lymphoma in Older Patients
Mengyang Di et al.
ONCOLOGIST (2021)
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
Juan-Manuel Sancho et al.
CANCER MEDICINE (2021)
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi
Francesco Merli et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis
Carlo Visco et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from theCardio-OncologyStudyGroup of theHeartFailureAssociation of theEuropeanSociety ofCardiology in collaboration with theInternationalCardio-OncologySociety
Alexander R. Lyon et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
Marijke Linschoten et al.
LANCET HAEMATOLOGY (2020)
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity
Luigi Rigacci et al.
HEMATOLOGICAL ONCOLOGY (2020)
Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Adam J. Olszewski et al.
BLOOD (2020)
Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Guido Gini et al.
BLOOD (2019)
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi
Stefano Luminari et al.
HEMATOLOGICAL ONCOLOGY (2018)
Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80years of age or older: a single-center retrospective study
Giuseppina Ricciuti et al.
HEMATOLOGICAL ONCOLOGY (2018)
Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin
Jacopo Olivieri et al.
ONCOLOGIST (2017)
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT] (NHL-14)
Michael A. Fridrik et al.
EUROPEAN JOURNAL OF CANCER (2016)
Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy
Lin Wang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases
Sarah Rohlfing et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
Frederic Peyrade et al.
LANCET ONCOLOGY (2011)
Nonpegylated liposomal doxorubicin (Myocet™) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial
S. Luminari et al.
ANNALS OF ONCOLOGY (2010)
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines
Luigi Rigacci et al.
HEMATOLOGICAL ONCOLOGY (2007)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
Mary C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Trastuzumab treatment and the risk of central nervous system (CNS) metastases
M. C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults
O Hequet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
CE Swenson et al.
ANTI-CANCER DRUGS (2003)
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma
S Limat et al.
ANNALS OF ONCOLOGY (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
G Batist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
